TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00850512
Drug: Zevalin
Normalized name: Zevalin KIT
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-week safety period for Zevalin
Study: NCT03064282
Drug: papaverine
Normalized name: Papaverine
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: observation of symptoms
Study: NCT05545397
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
Study: NCT06128837
Drug: Irinotecan hydrochloride liposome Injection
Normalized name: irinotecan hydrochloride liposome Injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk
Study: NCT06128837
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan 1.2 mg/m² intravenously Days 1-5 q3w
Study: NCT06270225
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
Study: NCT06270225
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
Study: NCT06270225
Drug: Colchicine 0.5 mg
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive 0.5mg/d Colchicine for 12 weeks.
Study: NCT05575518
Drug: Optimised rifamycin
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: optimised dose rifampicin with or without moxifloxacin
Study: NCT06069063
Drug: Zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander
Study: NCT04967430
Drug: Peginterferon Lambda-1A
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
Study: NCT05427630
Drug: Sham Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis flower from which the THC and CBD have been extracted
Study: NCT05171530
Drug: Lenvatinib plus taxane drugs
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA
Study: NCT01539265
Drug: silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06619509
Drug: Brigimadlin
Normalized name: Brigimadlin
DrugBank: Brigimadlin (DB18578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigimadlin
Study: NCT06512428
Drug: simmitinib plus irinotecan liposome
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
Study: NCT06512428
Drug: irinotecan liposome
Normalized name: Irinotecan liposome
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan liposome 70 mg/m\^2 every 2 weeks
Study: NCT06512428
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan 180mg/m\^2 every 2 weeks
Study: NCT04309721
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
Study: NCT05165394
Drug: NBI-1065846
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT06111326
Drug: Durvalumab injection
Normalized name: durvalumab Injection
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
Study: NCT06211283
Drug: Sodium valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fasted
Study: NCT06211283
Drug: Sodium valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fed
Study: NCT04573777
Drug: Repatha
Normalized name: Repatha
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
Study: NCT05424692
Drug: 5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
Study: NCT04745832
Drug: Zandelisib
Normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
Study: NCT04745832
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab IV 375 mg/m2 for 6 cycles
Study: NCT04745832
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
Study: NCT04745832
Drug: CHOP
Normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
Study: NCT06508983
Drug: pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
Study: NCT06508983
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
Study: NCT05134974
Drug: Phentolamine Ophthalmic Solution 0.75%
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Study: NCT05134974
Drug: Phentolamine Ophthalmic Solution Vehicle
Normalized name: phentolamine Ophthalmic Solution
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentolamine Ophthalmic Solution Vehicle
Study: NCT06485544
Drug: Adebrelimab + Etoposide + Platinum-based Therapy
Normalized name: platinum
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention Description for Treatment Group:~This intervention includes Adebrelimab in combination with Etoposide and Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Adebrelimab is administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle, followed by Etoposide at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment.
Study: NCT06485544
Drug: Etoposide + Platinum-based Therapy
Normalized name: platinum
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention Description for Control Group:~This intervention includes Etoposide in combination with Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Etoposide is administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment.
Study: NCT06097585
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: case control study in which group will receive SGLT2I and group will not , to detect impact of the drug in changing NYHA class for heart failure and echographic parameter
Study: NCT05293938
Drug: Obeticholic Acid 5 MG
Normalized name: obeticholic acid 5 MG
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: once daily, oral administration
Study: NCT05293938
Drug: Obeticholic Acid 10 MG
Normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: once daily, oral administration
Study: NCT06060080
Drug: pegylated recombinant human granulocyte-colony stimulating factor
Normalized name: Glycosylated recombinant granulocyte colony stimulating factor
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
Study: NCT00001081
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05123287
Drug: PD-1 immune checkpoint blockades
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
Study: NCT04978753
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;
Study: NCT05533125
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication
Study: NCT06665568
Drug: Intranasal ketamine hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)
Study: NCT05111249
Drug: Branaplam
Normalized name: Branaplam
DrugBank: Branaplam (DB14918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.
Study: NCT05635838
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study: NCT06137300
Drug: Urinary kallidinogenase for injection
Normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary kallidinogenase 0.15PNA once daily for 7 days.
Study: NCT05144542
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smoke usual brand of cigarettes
Study: NCT05144542
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vape e-cigarettes
Study: NCT05247177
Drug: dexmedetomidine, ketamine co-administration with sevoflurane for general anesthesia
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: co-administration of sevoflurane, iv. dexmedetomidine and iv. ketamine to maintain a predefined EEG density spectrum array pattern for general anesthesia
Study: NCT05247177
Drug: Conventional general anesthesia by administration of sevoflurane alone
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of sevoflurane alone to maintain anesthesia with a bispectral index between 40-60
Study: NCT04685473
Drug: T-1101 (Tosylate)
Normalized name: T-5224
DrugBank: FT-1101 (DB17553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-1101 (Tosylate) Capsule
Study: NCT06247540
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Receive PO
Study: NCT05153408
Drug: osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib tablets for oral administration
Study: NCT05153408
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion of carboplatin
Study: NCT05153408
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion of pemetrexed
Study: NCT04918589
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
Study: NCT05089305
Drug: Ozone plasma
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
Study: NCT04841343
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone in sinus
Study: NCT06699602
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: cemiplimab IV flat
Study: NCT06699602
Drug: Fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fianilmab IV flat
Study: NCT06613100
Drug: Xaluritamig
Normalized name: Xaluritamig
DrugBank: Xaluritamig (DB18137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT00000110
Drug: dietary fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05507606
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: osimertinib 80mg/d
Study: NCT05507606
Drug: Bevacizumab Biosimilar IBI305
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
Study: NCT05507606
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC5, d1; was stopped after 4 cycles
Study: NCT05507606
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
Study: NCT04725331
Drug: Pembrolizumab [KEYTRUDA®]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Study: NCT06388720
Drug: Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml.
Study: NCT04516902
Drug: Lysergic Acid Diethylamide
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 100 μg LSD will be administered.
Study: NCT04516902
Drug: 3,4-methylenedioxymethamphetamine
Normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 100 mg MDMA will be administered.
Study: NCT05689827
Drug: Ethyl methyl hydroxypyridine succinate + Meldonium
Normalized name: 2-ethyl-6-methyl-3-hydroxypyridine
DrugBank: Meldonium (DB13723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
Study: NCT05975307
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively.
Study: NCT05975307
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles.
Study: NCT05975307
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles.
Study: NCT05975307
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate \< 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles.
Study: NCT05748600
Drug: Dexpramipexole Dihydrochloride
Normalized name: Pramipexole Dihydrochloride
DrugBank: Dexpramipexole (DB15130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of dexpramipexole tablet
Study: NCT04938609
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
Study: NCT00000960
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06318676
Drug: Mezigdomide
Normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05593601
Drug: Neomycin
Normalized name: Neomycin
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
Study: NCT04853797
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg oral Ivabradine.
Study: NCT05669885
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will be allocated to receive oral administration of 100 mg sildenafil.
Study: NCT06202261
Drug: Paclitaxel for injection (albumin-bound)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It is an anti-microtubule chemotherapy drug
Study: NCT06202261
Drug: Fulvestrant injection
Normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
Study: NCT06202261
Drug: Vinorelbine tartrate injection
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine is an anti-tumor drug of vinca alkaloids.